BCRX BioCryst Pharmaceuticals, Inc.

7.320USD+0.27%Mkt Cap: 1.88B USDP/E: —

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuramini…

Institutional holders20 on file

Key Statistics

Company
Market Cap1.88B USD
Enterprise Value2.33B USD
Revenue (TTM)961.51M USD
Gross Profit855.76M USD
Net Income (TTM)263.86M USD
Revenue/Share3.99 USD
Last Price7.320 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees435
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)8.56
PEG9.39
EV/EBITDA4.93
EV/Revenue2.42
P/S1.96
P/B-4.72
EPS (TTM)-1.28 USD
EPS (Forward)0.85 USD
52W Range
6.23022% of range11.22
52W High11.22 USD
52W Low6.230 USD
Profitability
Gross Margin97.82%
Oper. Margin48.75%
EBITDA Margin49.14%
Profit Margin30.16%
ROE-221.45%
ROA51.32%
ROIC748.18%
ROCE107.20%
Growth
Revenue Growth13.10%
Earnings Growth133.30%
Cash Flow & Leverage
Operating CF347.37M USD
CapEx (TTM)2.47M USD
FCF Margin31.31%
FCF Yield15.99%
Net Debt453.20M USD
Net Debt/EBITDA0.96
Net Debt/FCF1.51
Balance Sheet
Debt/Equity-3.68
Current Ratio2.71
Quick Ratio2.54
Book Value/Sh-1.55 USD
Cash/Share1.46 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.45 USD
Upside (mean)+179.4%
Target Range11.00 USD – 32.00 USD
11.00+179.4% to mean32.00
# Analysts11
Ownership
Shares Out.257.30M
Float224.08M
Insiders1.27%
Institutions95.03%
Short Interest
Short Ratio5.1d
Short % Float10.82%
Short % Out.10.74%
Shares Short27.64M
Short (prev mo.)27.49M
Technical
SMA 508.182 (-10.5%)
SMA 2008.805 (-16.9%)
Beta0.51
S&P 52W Chg12.08%
Avg Vol (30d)4.82M
Avg Vol (10d)5.96M
Technical Indicators
RSI (14)36.6
MACD-0.2379
MACD Signal-0.1958
MACD Hist.-0.0420
BB Upper8.679 USD
BB Middle7.852 USD
BB Lower7.024 USD
BB Width21.07%
ATR (14)0.3274 USD
Vol Ratio (20d)0.80x

About BioCryst Pharmaceuticals (NASDAQ: BCRX)

›

BioCryst Pharmaceuticals (NASDAQ: BCRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 435 employees.

The shares were at 7.320 USD on 19 November 2026, up 4.1% over 52 weeks. Its 52-week range is 6.230 USD to 11.22 USD: the price is 34.8% below the high and 17.5% above the low.

Its market capitalisation is 1.88B USD.

BioCryst Pharmaceuticals reports return on equity of -221.4%, an operating margin of 48.8% and revenue up 13.1% year over year.

Its debt exceeds its cash by 453.20M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 20.45 USD is 179.4% above the current price. The next earnings report is expected on 25 February 2027.